Abstract:Gene therapy following gene transfer into hematopoietic cells (CD34+) is now being investigated for several genetic disorders. We have applied a similar approach using interferon gene transfer for treatment of chronic myelogenous leukemia (CML). IFN-α produces a hematologic and cytogenetic response in CML with a survival advantage for cytogenetic responders. Therefore, we examined the effect of transient over- expression of IFN-α using the adenovirus gene transfer approach. The ability of the adenovirus (Adv)-IFN-α gene construct to transfect normal and CML stem cells, CD34+, was examined. The peripheral blood mononuclear fraction from patients with CML treated with G-CSF or GM-CSF/G-CSF was enriched in CD34+ cells. Adv- cytomegalovirus (pCMV) promoter driven IFN-α at multiple doses was assessed to transfect highly purified CD34+ cells in the presence of matrix protein and in co- cultures with the stromal adherent cell layer. The use of cytokines enhances Adv- mediated IFN-α gene transfer into stem cells. Southern blot analysis demonstrated that the Adv-pCMV-IFN-α construct and IFN-α were expressed in cultured CD34+. Transient expression of the IFN-α gene did not suppress proliferation of CD34+ progenitors, CFU-Meg, BFU-E or CFU-CM growth. Reverse transcriptase/polymerase chain reaction (RT/PCR) analysis of RNA from CFU-GM progenitor cells demonstrated transient IFN-α mRNA expression in CD34+ cells. Immunoassay of IFN-α shows that IFN-α suggests that selective expression of IFN-α may be beneficial for CML therapy. We also report on the establishment of novel conditions which permit high efficiency of the retrovirus IFN-α gene into CD34+ cells. Stem cells transfected with retrovirus were infused intravenously to irradiated mice and spleen colony forming units were evaluated for IFN-α marked clones by Southern blot analysis. These studies demonstrate that the overexpression of IFN-α gene can be used suppression of K562 cell proliferation and suggest its possible use as gene therapy of CML. For permanent transfection, we constructed two IFNα cDNA-containing retroviral vectors LSN-IFNα was constructed by cloning human IFNα cDNA at the downstream of the 5′ long terminal repeat (LTR) promoter of the retroviral vector LXSN. Retrovirus-containing supernatants from PA317 cell line was used to infect NIH3T3 fibroblasts and K562 cells. The IFNα gene expression in transfected cells was confirmed by Northern Blot, RT-PCR, radioimmunoassay (RIA), and biological assay. Retroviral mediated IFN-α gene transfer infection results showed that cell proliferation and cell viability were significantly suppressed in LSN-IFNαa-infected K562 cells as compared to LXSN-infected K562. Furthermore, we found that retroviral mediated IFN-α causes upregulation of adhesion molecules such as VLA-4.

Genetic engineering of hematopoiesis for targeted IFN-α delivery inhibits breast cancer progression

Genetic Engineering of Hematopoiesis for Targeted IFN-α Delivery Inhibits Breast Cancer Progression

Effects of gamma-interferon gene-modified hepatocytes on murine implanted liver carcinoma

Hematopoietic stem cell gene therapy targeting TGFβ enhances the efficacy of irradiation therapy in a preclinical glioblastoma model

[Influence of Mouse Genetic Engineering Regulatory T Cells Infusion on Post-Allogeneic Bone Marrow Transplantation Acute Graft-Versus-host Disease in Mice].

Genetically Engineered Hematopoietic Stem Cells Deliver TGF‐β Inhibitor to Enhance Bone Metastases Immunotherapy

668. Platelets Engineered to Express Interleukin-24 Inhibited Melanoma Tumor Growth in Mice

Influence of the lentiviral vectors-mediated mouse genetic engineering Treg after allogeneic bone marrow transplantation on graft-versus-hostdiseaseinmice

Efficacy assessment of interferon-alpha-engineered mesenchymal stromal cells in a mouse plasmacytoma model

Genetically Engineered Bone Marrow-Derived Mesenchymal Stem Cells Co-Expressing IFN-γ and IL-10 Inhibit Hepatocellular Carcinoma by Modulating MAPK Pathway.

Selective Targeting of Interferon γ to Stromal Fibroblasts and Pericytes as a Novel Therapeutic Approach to Inhibit Angiogenesis and Tumor Growth

Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy

Effect of Retrovirus and Adenovirus Mediated Interferon Gene Transfer on Hematopoietic Progenitor Cell Growth

Targeted inducible delivery of immunoactivating cytokines reprograms glioblastoma microenvironment and inhibits growth in mouse models

Anti-Angiogenesis Therapy Based on the Bone Marrow-Derived Stromal Cells Genetically Engineered to Express Sflt-1 in Mouse Tumor Model

"Active" cancer immunotherapy by anti-Met antibody gene transfer

Immune system augmentation via humanization using stem/progenitor cells and bioengineering in a breast cancer model study

The Effect of Interferon-β on Endothelial Progenitor Cell-induced Tumor Angiogenesis

Retrovirus and Adenovirus-Mediated Interferon Gene Transfer into Hematopoietic Stem Cells (CD 34+) of Normal and Chronic Myelogenous Leukemia

Dual Targeted Immunotherapy Via in Vivo Delivery of Biohybrid RNAi‐Peptide Nanoparticles to Tumor‐Associated Macrophages and Cancer Cells

Suppression of cancer growth in mice by adeno-associated virus vector-mediated IFN-β expression driven by hTERT promoter